# Janssen Research & Development, LLC trials: 933 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 933 trials with Janssen Research & Development, LLC as lead sponsor, 76 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Janssen Research & Development, LLC: 933 rows for $46.65, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 933
- Recruiting or not yet: 76
- Read on: November 19, 2026

## Trials

The 25 newest of 933, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943078 | A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors | Janssen Research & Development, LLC | Phase 1 | Not yet recruiting | Neoplasms | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943078) |
| November 4, 2026 | NCT07915232 | A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to Nipocalimab | Janssen Research & Development, LLC | Observational | Not yet recruiting | Pregnancy Related, Pregnancy, Pregnancy High-risk | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915232) |
| October 30, 2026 | NCT07906717 | A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 3 | Recruiting | Prostatic Neoplasms | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906717) |
| October 29, 2026 | NCT07903272 | A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants... | Janssen Research & Development, LLC | Phase 3 | Not yet recruiting | Multiple Myeloma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903272) |
| September 21, 2026 | NCT07832292 | A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer | Janssen Research & Development, LLC | Phase 2 | Recruiting | Prostatic Neoplasms | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832292) |
| September 16, 2026 | NCT07822529 | A Study of Long Term Persistency of Guselkumab in Adult Participants With Inflammatory Bowel Disease | Janssen Research & Development, LLC | Observational | Recruiting | Inflammatory Bowel Diseases | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822529) |
| August 5, 2026 | NCT07746713 | A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer | Janssen Research & Development, LLC | Phase 1 | Recruiting | Prostatic Neoplasms | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746713) |
| August 5, 2026 | NCT07746687 | A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma | Janssen Research & Development, LLC | Phase 2 | Recruiting | Asthma | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07746687) |
| July 21, 2026 | NCT07716098 | A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression | Janssen Research & Development, LLC | Phase 3 | Recruiting | Depressive Disorder, Treatment-Resistant | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716098) |
| June 25, 2026 | NCT07669077 | A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women | Janssen Research & Development, LLC | Phase 1 | Recruiting | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669077) |
| June 24, 2026 | NCT07665450 | A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide... | Janssen Research & Development, LLC | Phase 3 | Recruiting | Multiple Myeloma | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665450) |
| June 17, 2026 | NCT07654751 | A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | Janssen Research & Development, LLC | Phase 4 | Recruiting | Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654751) |
| May 29, 2026 | NCT07615426 | A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia | Janssen Research & Development, LLC | Phase 1 | Recruiting | Schizophrenia | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07615426) |
| May 22, 2026 | NCT07602088 | A Real-world Study of Ibrutinib and Venetoclax (I+V) First-Line Treatment Given for Fixed-duration of Time in Participants With Chronic... | Janssen Research & Development, LLC | Observational | Recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602088) |
| May 15, 2026 | NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants... | Janssen Research & Development, LLC | Phase 2 | Recruiting | Multiple Myeloma | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589634) |
| May 14, 2026 | NCT07586202 | A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC | Janssen Research & Development, LLC | Phase 2 | Recruiting | Carcinoma, Non-Small-Cell Lung | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586202) |
| May 13, 2026 | NCT07582783 | A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania | Janssen Research & Development, LLC | Observational | Recruiting | Psoriasis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582783) |
| May 11, 2026 | NCT07577856 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis | Janssen Research & Development, LLC | Phase 3 | Recruiting | Colitis, Ulcerative | 644 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577856) |
| May 11, 2026 | NCT07577843 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | Phase 3 | Recruiting | Crohn Disease | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07577843) |
| May 7, 2026 | NCT07573176 | A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder | Janssen Research & Development, LLC | Phase 3 | Recruiting | Depressive Disorder, Major | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573176) |
| May 7, 2026 | NCT07572006 | A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | Janssen Research & Development, LLC | Phase 1 | Recruiting | Hematologic Neoplasms | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07572006) |
| April 21, 2026 | NCT07541261 | A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia | Janssen Research & Development, LLC | Observational | Recruiting | Colitis, Ulcerative, Crohn Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541261) |
| April 13, 2026 | NCT07524855 | A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer | Janssen Research & Development, LLC | Phase 1 | Recruiting | Metastatic Breast Cancer | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07524855) |
| April 8, 2026 | NCT07518186 | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Janssen Research & Development, LLC | Phase 3 | Recruiting | Multiple Myeloma | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518186) |
| March 30, 2026 | NCT07499232 | A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | Janssen Research & Development, LLC | Phase 3 | Recruiting | Crohn Disease | 530 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499232) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 13 |
| Phase 1 | 400 |
| Phase 1/2 | 25 |
| Phase 2 | 184 |
| Phase 2/3 | 12 |
| Phase 3 | 200 |
| Phase 4 | 17 |
| Not applicable | 19 |
| Observational | 63 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 642 |
| Active not recruiting | 89 |
| Terminated | 79 |
| Recruiting | 73 |
| Withdrawn | 26 |
| No longer available | 10 |
| Approved for marketing | 8 |
| Not yet recruiting | 3 |
| Temporarily not available | 1 |
| Suspended | 1 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 64 |
| Prostatic Neoplasms | 41 |
| Depressive Disorder, Major | 38 |
| Diabetes Mellitus, Type 2 | 32 |
| Crohn Disease | 25 |
| Carcinoma, Non-Small-Cell Lung | 24 |
| Colitis, Ulcerative | 23 |
| Arthritis, Psoriatic | 19 |
| Alzheimer Disease | 19 |
| Neoplasms | 19 |
| Psoriasis | 18 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 17 |
| Schizophrenia | 17 |
| Depressive Disorder, Treatment-Resistant | 16 |
| Arthritis, Rheumatoid | 16 |
| Lymphoma, Non-Hodgkin | 14 |
| Leukemia, Myeloid, Acute | 12 |
| Recurrence | 11 |
| Lymphoma, Mantle-Cell | 10 |
| Lymphoma, Follicular | 10 |
| Depression | 9 |
| Lupus Erythematosus, Systemic | 9 |
| Dermatitis, Atopic | 8 |
| Colorectal Neoplasms | 8 |
| Prostatic Neoplasms, Castration-Resistant | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [Publishers in the United States](https://specstream.ai/data/businesses/publishers/united-states)
- [Middle Eastern restaurants in the United States](https://specstream.ai/data/businesses/middle-eastern-restaurants/united-states)
- [Home staging companies in the United States](https://specstream.ai/data/businesses/home-staging-companies/united-states)
- [Educational supply stores in the United States](https://specstream.ai/data/businesses/educational-supply-stores/united-states)
- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
